查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1869710

美国避孕产品市场规模、份额和趋势分析报告：产品和细分市场预测（2025-2033）

U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国避孕产品市场规模及趋势：

预计到 2024 年，美国避孕产品市场价值将达到 80.8 亿美元，到 2033 年将达到 123.7 亿美元。

预计2025年至2033年间，该市场将以4.88%的复合年增长率成长。现代避孕产品的使用率不断提高，以及青少年和年轻人对性健康和计划生育的意识提升，是推动这一增长的主要因素。此外，政府计画也正在扩大避孕产品的取得途径，有助于预防青少年意外怀孕。

女性避孕健康领域的持续创新

随着人们对可靠替代方案的需求、意识和偏好不断提高，各公司致力于提供安全、有效和长期的避孕选择，以满足世界各地女性不断变化的需求，从而推动了相关技术的重大进步和新产品的推出。

Anyloring：扩大避孕选择

2023年10月，Xiromed LLC推出了Eniloring（依托孕烯/炔雌醇阴道环），它是NuvaRing的学名药。该产品提供长效避孕效果，是Xiromed公司广泛的女性药品产品线的重要扩展，该产品线还包括口服避孕药和经皮凝胶。

Xiromed执行长Rob Spina就此次发布的重要意义发表了评论：

“Eniloring的上市标誌着我们在成为美国领先的女性健康保健产品学名药供应商的征程中迈出了激动人心的一步。我们致力于为美国患者拓展和改善避孕选择。”

Eniloring 由西班牙莱昂的 Laboratorios Leon Pharma 生产，体现了 Siromed 致力于利用尖端技术的承诺，也是 Insad Pharma 致力于推动女性健康解决方案的一部分。

目录

第一章调查方法和范围

第二章执行摘要

第三章 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场趋势与展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 法律规范
  • 商业环境分析工具
    • 产业分析—波特五力分析
    • PESTEL 分析

第四章 产品业务分析

  • 美国避孕产品市场：产品差异分析
  • 美国避孕产品市场：产品细分仪表板
  • 2024年及2033年产品趋势及市占率分析
  • 副产品
  • 药片
  • 子宫内避孕器（IUD）
    • 子宫内激素装置
    • 非荷尔蒙子宫内避孕器
  • 保险套
    • 男用保险套
    • 女性用保险套
  • 避孕环
  • 皮下植入
  • 注射
  • 其他的

第五章 竞争情势

  • 公司分类
  • 企业市场分析，2024年
  • 策略规划
    • 併购
    • 伙伴关係与合作
    • 新产品上市
    • 其他的
  • 公司简介
    • Church &Dwight Co., Inc.
    • Reckitt Benckiser Group Plc
    • Organon Group of Companies
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • The Cooper Companies, Inc.
    • Agile Therapeutics
    • Mayer Laboratories, Inc.
    • Mayne Pharma Group Limited.
    • Bayer AG
    • Afaxys, Inc.
    • AbbVie
    • Gedeon Richter
Product Code: GVR-2-68038-702-5

U.S. Contraceptive Market Size & Trends:

The U.S. contraceptive market size was valued at USD 8.08 billion in 2024 and is expected to reach USD 12.37 billion by 2033, growing at a CAGR of 4.88% from 2025 to 2033. The increase in the use of modern contraceptives and the rise in awareness among adolescents and young people about sexual health and family planning are key factors driving growth. Moreover, government programs have led to an increase in access to contraceptives that help prevent unwanted pregnancies in teenagers.

Continued Innovation in Women's Contraceptive Health

With the increasing demand, awareness, and preference for reliable alternatives, companies are looking forward to offering safe, effective, and long-term contraceptive options to meet the evolving needs of women worldwide, leading to notable advancements and product launches.

EnilloRing: Expanding Contraceptive Choices

In October 2023, Xiromed LLC introduced EnilloRing (etonogestrel/ethinyl estradiol vaginal ring), a generic alternative to NuvaRing. This product offers long-lasting contraceptive protection and marks an important expansion of Xiromed's extensive range of women's health medications, which also feature oral contraceptives and transdermal gels.

Rob Spina, CEO of Xiromed, highlighted the impact of this launch:

"The launch of EnilloRing is an exciting milestone in Xiromed's journey to becoming a leading generic provider of women's healthcare products in the United States. We are committed to broadening and growing the availability of contraceptive options for U.S. patients."

Manufactured at Laboratorios Leon Pharma SAU in Leon, Spain, EnilloRing underscores Xiromed's dedication to leveraging cutting-edge technologies as part of Insud Pharma's commitment to advancing women's health solutions.

U.S. Contraceptive Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. contraceptive market report based on product.

  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Pills
  • Intrauterine Devices (IUD)
    • Hormonal IUD
    • Nonhormonal IUD
  • Condoms
    • Male Condoms
    • Female Condoms
  • Vaginal Ring
  • Subdermal Implants
  • Injectable
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
    • 1.8.3. Objective - 3
  • 1.9. List of Secondary Sources
  • 1.10. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. U.S. Contraceptive Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
      • 2.1.2.1. Product segment outlook
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Regulatory Framework
  • 3.5. Business Environment Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis

Chapter 4. Product Business Analysis

  • 4.1. U.S. Contraceptive Market: Product Movement Analysis
  • 4.2. U.S. Contraceptive Market: Product Segment Dashboard
  • 4.3. Product Movement & Market Share Analysis, 2024 & 2033
  • 4.4. U.S. Contraceptive Market Estimates & Forecast, by Product
  • 4.5. Pills
    • 4.5.1. Pills Market, 2021 - 2033 (USD Million)
  • 4.6. Intrauterine Devices (IUD)
    • 4.6.1. Intrauterine Devices (IUD) Market, 2021 - 2033 (USD Million)
    • 4.6.2. Hormonal IUD
      • 4.6.2.1. Hormonal IUD market, 2021 - 2033 (USD Million)
    • 4.6.3. Nonhormonal IUD
      • 4.6.3.1. Nonhormonal IUD market, 2021 - 2033 (USD Million)
  • 4.7. Condoms
    • 4.7.1. Condoms Market, 2021 - 2033 (USD Million)
    • 4.7.2. Male Condoms
      • 4.7.2.1. Male condoms market, 2021 - 2033 (USD Million)
    • 4.7.3. Female Condoms
      • 4.7.3.1. Female condoms market, 2021 - 2033 (USD Million)
  • 4.8. Vaginal Ring
    • 4.8.1. Vaginal Ring Market, 2021 - 2033 (USD Million)
  • 4.9. Subdermal Implants
    • 4.9.1. Subdermal Implants Market, 2021 - 2033 (USD Million)
  • 4.10. Injectable
    • 4.10.1. Injectable Market, 2021 - 2033 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Competitive Landscape

  • 5.1. Company Categorization
  • 5.2. Company Market Position Analysis, 2024
  • 5.3. Strategy Mapping
    • 5.3.1. Mergers & Acquisitions
    • 5.3.2. Partnership and Collaborations
    • 5.3.3. New Product Launch
    • 5.3.4. Others
  • 5.4. Company Profiles/Listing
    • 5.4.1. Church & Dwight Co., Inc.
      • 5.4.1.1. Overview
      • 5.4.1.2. Financial performance
      • 5.4.1.3. Product benchmarking
      • 5.4.1.4. Strategic initiatives
    • 5.4.2. Reckitt Benckiser Group Plc
      • 5.4.2.1. Overview
      • 5.4.2.2. Financial performance
      • 5.4.2.3. Product benchmarking
      • 5.4.2.4. Strategic initiatives
    • 5.4.3. Organon Group of Companies
      • 5.4.3.1. Overview
      • 5.4.3.2. Financial performance
      • 5.4.3.3. Product benchmarking
      • 5.4.3.4. Strategic initiatives
    • 5.4.4. Pfizer, Inc.
      • 5.4.4.1. Overview
      • 5.4.4.2. Financial performance
      • 5.4.4.3. Product benchmarking
      • 5.4.4.4. Strategic initiatives
    • 5.4.5. Teva Pharmaceutical Industries Ltd.
      • 5.4.5.1. Overview
      • 5.4.5.2. Financial performance
      • 5.4.5.3. Product benchmarking
      • 5.4.5.4. Strategic initiatives
    • 5.4.6. The Cooper Companies, Inc.
      • 5.4.6.1. Overview
      • 5.4.6.2. Financial performance
      • 5.4.6.3. Product benchmarking
      • 5.4.6.4. Strategic initiatives
    • 5.4.7. Agile Therapeutics
      • 5.4.7.1. Overview
      • 5.4.7.2. Financial performance
      • 5.4.7.3. Product benchmarking
      • 5.4.7.4. Strategic initiatives
    • 5.4.8. Mayer Laboratories, Inc.
      • 5.4.8.1. Overview
      • 5.4.8.2. Financial performance
      • 5.4.8.3. Product benchmarking
      • 5.4.8.4. Strategic initiatives
    • 5.4.9. Mayne Pharma Group Limited.
      • 5.4.9.1. Overview
      • 5.4.9.2. Financial performance
      • 5.4.9.3. Product benchmarking
      • 5.4.9.4. Strategic initiatives
    • 5.4.10. Bayer AG
      • 5.4.10.1. Overview
      • 5.4.10.2. Financial performance
      • 5.4.10.3. Product benchmarking
      • 5.4.10.4. Strategic initiatives
    • 5.4.11. Afaxys, Inc.
      • 5.4.11.1. Overview
      • 5.4.11.2. Financial performance
      • 5.4.11.3. Product benchmarking
      • 5.4.11.4. Strategic initiatives
    • 5.4.12. AbbVie
      • 5.4.12.1. Overview
      • 5.4.12.2. Financial performance
      • 5.4.12.3. Product benchmarking
      • 5.4.12.4. Strategic initiatives
    • 5.4.13. Gedeon Richter
      • 5.4.13.1. Overview
      • 5.4.13.2. Financial performance
      • 5.4.13.3. Product benchmarking
      • 5.4.13.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Contraceptive methods and associated side effects
  • Table 4 Classification of contraceptives by the U.S. FDA
  • Table 5 States that have expanded contraceptive coverage guarantee in the Affordable Care Act
  • Table 6 Types of oral contraceptives, composition, and regimen
  • Table 7 List of intrauterine devices currently available in the U.S.
  • Table 8 Types of male condom variants
  • Table 9 US contraceptive market revenue estimates and forecast, by product, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. contraceptive market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. contraceptive market: Parent market outlook
  • Fig. 13 U.S. contraceptive market dynamics
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 U.S. contraceptive market: Porter's five forces analysis
  • Fig. 17 U.S. contraceptive market: PESTLE analysis
  • Fig. 18 U.S. contraceptive market: product segment dashboard
  • Fig. 19 U.S. contraceptive market: product market share analysis, 2024 & 2033
  • Fig. 20 Pills market, 2021 - 2033 (USD Million)
  • Fig. 21 Intrauterine Devices (IUD) market, 2021 - 2033 (USD Million)
  • Fig. 22 Hormonal IUD market, 2021 - 2033 (USD Million)
  • Fig. 23 Nonhormonal IUD market, 2021 - 2033 (USD Million)
  • Fig. 24 Condoms market, 2021 - 2033 (USD Million)
  • Fig. 25 Male condoms market, 2021 - 2033 (USD Million)
  • Fig. 26 Female condoms market, 2021 - 2033 (USD Million)
  • Fig. 27 Vaginal ring market, 2021 - 2033 (USD Million)
  • Fig. 28 Subdermal implants market, 2021 - 2033 (USD Million)
  • Fig. 29 Injectable market, 2021 - 2033 (USD Million)
  • Fig. 30 Others market, 2021 - 2033 (USD Million)
  • Fig. 31 Company/competition categorization
  • Fig. 32 Company market position analysis
  • Fig. 33 U.S. contraceptive market: Strategy mapping